GeneralConnection.com ➔ Dictionary
Dictionary Search

myeloma

Synonyms

Noun

1. malignant tumor

2. malignant neoplasm, metastatic tumor

Usage
FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma - Pharmaceutical Executive
Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector - Fierce Pharma
The Future of Myeloma Treatment: Ajai Chari, MD - Journal of Managed Care
FDA Approves Subcutaneous Isatuximab-irfc for Multiple Myeloma - Oncology Nursing News
Sanofi injectable multiple myeloma drug approved (SNY:NASDAQ) - Seeking Alpha
FDA Approves Sarclisa Escena as a New Under the Skin Treatment Option for Multiple Myeloma - Cure Today
FDA Approves Subcutaneous Isatuximab in Multiple Myeloma - CancerNetwork
FDA thumbs up for Sanofi’s subcutaneous Sarclisa Escena - The Pharma Letter
Shoulder pain leads to Texas dad's cancer diagnosis: "I was like, 'Wait, what?'" - CBS News
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy - The New England Journal of Medicine
FDA Approves Subcutaneous Isatuximab for Multiple Myeloma Indications - Oncology News Central
Relapsed/Refractory Multiple Myeloma: Rationale and Design of the MonumenTAL-3 Study - CancerNetwork
FDA Approves Subcutaneous Isatuximab for Multiple Myeloma - Targeted Oncology
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma - OncLive
The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma - PharmTech.com
FDA Approves Isatuximab-Irfc For Subcutaneous Injection For Multiple Myeloma Indications On July 9 - TradingView
EHA 2026: Dr Rahul Banerjee Discusses New Options in Multiple Myeloma (Video) - Cancer Therapy Advisor
FDA Approves Subcutaneous Isatuximab-irfc - Conexiant
Optec/Optal: Peter Forsberg, MD, Highlights Key Multiple Myeloma Research Considerations From the Phase 2 Study - Cancer Nursing Today
Rejuvenating exhausted T cells improves immunotherapy for myeloma - Drug Discovery News
Relapsed/Refractory Multiple Myeloma: Interpreting MonumenTAL-3 Efficacy and Safety Findings - CancerNetwork
Further MonumenTAL-3 Follow-Up Needed for Triplet Regimen in Relapsed Myeloma - Targeted Oncology
The Growing Rationale for Earlier Targeting of GPRC5D in Multiple Myeloma - Targeted Oncology
First Relapse in Multiple Myeloma: Balancing Options, Sequencing Decisions, and Patient-Centered Care - Journal of Managed Care
Navigating toxicities in BCMA-directed multiple myeloma therapy - Oncology Central
CEPHEUS Trial and MRD Outcomes in Newly Diagnosed Multiple Myeloma - CancerNetwork
US FDA approves Sanofi's wearable injector form of blood cancer drug - Reuters
Refractory vs. Exposed: How Anti-CD38 Status Shapes Second-Line Treatment Decisions in Multiple Myeloma - Journal of Managed Care
Man’s Shoulder Pain Led to Life-Changing Myeloma Diagnosis: ‘Wait, What?’ - People.com
Why CELMoDs Pair Synergistically With PIs and CD38 Antibodies in Multiple Myeloma - CancerNetwork
Outpatient BiTE Therapy Model Expands Access for Patients With Multiple Myeloma - Pharmacy Times – Pharmacy Practice News and Expert Insights
Pharmacist-Led Workflows Support Safe Outpatient BiTE Therapy in Multiple Myeloma - Pharmacy Times – Pharmacy Practice News and Expert Insights
Press Release: Sanofi’s subcutaneous Sarclisa Escena - GlobeNewswire
Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, but Longer Follow-Up Needed: Rahul Banerjee, MD - Journal of Managed Care
Roles, Resources, and Relationships: The Stakeholder Framework Behind Successful Myeloma Care Transitions - Pharmacy Times – Pharmacy Practice News and Expert Insights
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial - nature.com
FDA approves Sanofi's Sarclisa Escena, first anticancer treatment administered via on-body injector - PharmaLive
Striving for a cure for multiple myeloma: What HCPs need to know - Johnson & Johnson
When It Works: Best-Case Scenarios and Lessons Learned From Successful Care Transitions in Myeloma - Pharmacy Times – Pharmacy Practice News and Expert Insights
Telo Genomics files provisional patent for blood-based myeloma test - Investing.com
Teclistamab Improves Outcomes in Relapsed Multiple Myeloma - University of Miami
Improving how multiple myeloma is understood and treated - Mayo Clinic News Network
Mezigdomide Drives 41% ORR in Triple-Class Refractory Multiple Myeloma - CancerNetwork
Smoldering Multiple Myeloma: From Clinical to Immunogenomic Risk Stratification and Therapeutic Implications of Early Intervention - ASCO Publications
Addition of Mezigdomide to Carfilzomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma - The ASCO Post
Survey Highlights Need for Nurse Autonomy in Multiple Myeloma Care - Oncology Nursing News
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial - nature.com
Reflecting on CAR T for First Relapse in Multiple Myeloma - Targeted Oncology
Multiple Myeloma: Diagnosis and Treatment - American Academy Of Family Physicians | AAFP
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal - nature.com
Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma - Journal of Managed Care
Relapsed/Refractory Multiple Myeloma: Expanding Beyond BCMA With GPRC5D Targeting - CancerNetwork
Smoldering multiple myeloma in transition: redefining early myeloma in the modern era - nature.com
Relapsed/Refractory Multiple Myeloma: Clinical Development and Early Experience With Talquetamab - CancerNetwork
Multiple Myeloma in Dogs: What It Is and How To Help Your Pet - PetMD
Sanofi (SNY) Secures FDA Approval for Subcutaneous Sarclisa Esce - GuruFocus
Is a Functional Cure for Multiple Myeloma Within Reach? - Cure Today
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word - CancerNetwork
Multiple Myeloma Trial Explores Immunotheraphy Option - Froedtert & MCW
Innovations extending survival in multiple myeloma therapy - Penn Medicine
Are multiple myeloma rates higher in Western New York? - Roswell Park Comprehensive Cancer Center
Minimal Residual Disease Testing in Multiple Myeloma - ASCO Daily News
Enhanced dynamic risk stratification of smoldering multiple myeloma - nature.com
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D | Leukemia - nature.com
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial - nature.com
Elranatamab Shows Strong Efficacy Signal in Smoldering Multiple Myeloma - CancerNetwork
Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials - nature.com
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study - nature.com
When Should Oncologists Treat Smoldering Multiple Myeloma? - ASCO Daily News
Protein marker may help predict myeloma outcomes - Rare Cancer News
Talquetamab Combinations in Relapsed or Refractory Myeloma - The ASCO Post
Multiple Myeloma: Shedding Light on a Rare but Complex Blood Cancer - Pfizer
Defining cure for multiple myeloma: Lu Anna’s story - Roswell Park Comprehensive Cancer Center
What Is Multiple Myeloma? Everything You Should Know - Health: Trusted and Empathetic Health and Wellness Information
Charting Progress, Changing Outcomes: The Evolution of Multiple Myeloma Care - Sanofi
CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target - nature.com
Seven Years of Treatment for Multiple Myeloma, Endless Opportunity - Dana-Farber Cancer Institute
The Multiple Myeloma Revolution Happening Right Now: Swarup Kumar, MD - Journal of Managed Care
Myeloma: How AI Is Redrawing the Map of Cancer Care - University of Miami
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma - Cure Today
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy - ASCO Publications
Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma - nature.com
CAR-T Moves to the Front Line: Rethinking the Multiple Myeloma Sequence - CancerNetwork
Delving into tRNA-derived small RNAs in multiple myeloma: elevated 3′U-tRF - nature.com
Diabetes mellitus in multiple myeloma and related plasma cell disorders: a review of risk, prognosis, and outcomes - nature.com
Leaving the Bone Marrow: Extramedullary Disease in Multiple Myeloma - Cancer Nursing Today
Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders - nature.com
Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma - The University of Alabama at Birmingham
Peripheral blood cfDNA detection using clonoSEQ assay in multiple myeloma is concordant with bone marrow and clinical biomarkers - nature.com
Bloodlines Series: What Is Smoldering Myeloma? - American Association for Cancer Research (AACR)
Real-world analysis of multiple myeloma treatments in England using the Cancer Analysis System registry - nature.com
Early CAR T Brings Questions of Preferred Bridging in Multiple Myeloma - Targeted Oncology
New treatment combination delays multiple myeloma progression and may improve survival, study finds - Atrium Health Wake Forest Baptist
Multiple Myeloma: Understanding the Unseen Burdens Beyond Disease - Sanofi
Mezigdomide Triplet Cuts Progression Risk by 52% in R/R Myeloma - Targeted Oncology
J&J multiple myeloma drug gains edge in earlier stage disease - BioPharma Dive
How effective is elranatamab for treating multiple myeloma in the real world? - Fred Hutchinson Cancer Center
Inflammatory immune cells predict survival, relapse in multiple myeloma - WashU Medicine
Multiple Myeloma: Improved Prognosis With the Latest Treatments - Memorial Sloan Kettering Cancer Center
How Has SC Daratumumab Affected Smoldering Multiple Myeloma Treatment? - CancerNetwork
Foreign Language Equivalents
Foreign Language Equivalents of 'myeloma'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
myelo,a,   myelpma,   mteloma,   nyeloma,   myelmoa,   myeeloma,   myelloma,   myelomaa,   myeloa,   yeloma,   myeolma,   myekoma,   myelooma,   myelona,   myelima,   meloma,   myrloma,   myelom,   myelomma,   mywloma,   myeoma,   mye;oma,   myyeloma,   meyloma,   myloma,   myeloam,   myeloms,   mueloma,   myelma,   mmyeloma,   myleoma,   ymeloma,   ,yeloma
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z